Intravenous Paracetamol or Morphine for the Treatment of Acute Flank Pain
Information source: Pamukkale University
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Urolithiasis
Intervention: paracetamol (Drug); morphine (Drug); Paracetamol (Drug); Paracetamol (Drug); Morphine (Drug)
Phase: Phase 4
Status: Completed
Sponsored by: Pamukkale University Official(s) and/or principal investigator(s): Mustafa Serinken, Proffesor, Study Director, Affiliation: Pamukkale University
Summary
STUDY OBJECTIVE: This randomized, controlled trial evaluates the analgesic efficacy and
safety of intravenous single-dose paracetamol and morphine for the treatment of acute flank
pain.
METHODS: The investigators conducted a randomized, double-blind, controlled clinical trial
comparing single intravenous doses of paracetamol (1 g) and morphine (0. 1 mg/kg) for
patients presenting to the emergency department (ED) with acute flank pain. Subjects with
inadequate pain relief at 30 minutes received rescue fentanyl (0. 75 microg/kg).
Clinical Details
Official title: Intravenous Paracetamol or Morphine for the Treatment of Acute Flank Pain : a Randomized, Double Blind, Controlled Clinical Trial
Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment
Primary outcome: Reduction in visual analogue scale
Secondary outcome: Adverse events.
Detailed description:
Study Design and Setting:
This is a single-center, prospective, randomized, double-blind, clinical trial performed in
an ED of a tertiary care hospital with annual census of approximately 37. 000 visits. The
local ethics committee approved the study.
Two treatment options, intravenous paracetamol and morphine, were compared for ceasing pain
in patients presented with renal colic.
Selection of Participants:
Patients, aged 18 to 55 years, with flank pain were accepted as eligible for the study.
Patients with clinical diagnosis of acute renal colic and declared to have moderate or
serious pain according to the 4-point verbal scale were included into the study.
Exclusion criteria were as follows: patients denied to give inform consent, use of any
analgesic within six hours of ED presentation, patients with fewer or hemodynamically
unstable, peritoneal irritation signs, cardiac failure, history of renal and hepatic
failure, prior known allergy to paracetamol or morphine, suspected or documented pregnancy
and patients with viewing problems. Patients suspected to have renal colic but ultimately to
have diagnosis such as renal abscess, renal infarction or renal venous thrombosis were also
excluded from the study.
Consecutive patients were enrolled into the study 24 hours a day and seven days a week by
the senior resident in the shift. The ultimate diagnosis of renal colic was performed by
displaying the stone either by ultrasonograph (USG) or computerized tomography (CT). USG was
the first choice for detecting the renal stone. CT was performed if a stone was not detected
by USG. After CT, patients who were not shown a urolithiasis or pathologies other than
renal colic were excluded from the study.
Interventions:
Study subjects were randomized in order to receive a single dose of either paracetamol
(Perfalgan, Bristol Myers Squibb, Itxassou, France), 1 gr in 100 ml normal saline, or
morphine (0. 1 mg/kg in 100 ml normal saline) in a blinded fashion. The study drugs was
written in a paper which is folded four times and covered with sealed bands for allocation
concealment. The study nurse withdrew one of the drugs from a box. And they were prepared by
the study nurse and administered by the second nurse blinded to the study. Study drugs were
identical in color and appearance. Subjects with who needed rescue drug because of
inadequate pain relief were received fentanyl 1 μg/kg intravenously.
Methods of Measurements:
Subjects reported pain intensity on both a 100-mm visual analogue scale (limited by 'no
pain' and 'the worst pain') and a 4-point verbal rating scale (no pain, mild, moderate, or
severe pain) just before the drug administration, 15th minutes and 30th minutes after the
study drug administration. The demographic features of study patients and adverse effects,
nausea, vomiting, dizziness, vertigo, headache, hypotension, altered mental status, allergic
reaction, itching, urinary retention, thoracic rigidity, respiratory depression and dry
mouth, were recorded to the study form.
Outcome Measures The primary outcome measure was the pain reduction in VAS and VRS at 15th
and 30th minutes. Secondary outcome measures were the need for rescue drug and the presence
of any adverse event.
Primary Data Analysis:
The present study was planned as a superiority trial. When the 20 mm difference in VAS is
accepted as clinically significant and the standard deviation is accepted as 25 mm, 35
patients are needed with each group with 95% power. All the analysis were implemented
according to the intention to treat analysis. The precise of differences between time
intervals within groups and between groups and statistical significance were expressed by
95% confidence intervals (95% CI). All tests of significance were two sided.
Eligibility
Minimum age: 16 Years.
Maximum age: 55 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
Adults (aged 16 to 55 years old) with acute low back pain were eligible for inclusion in
the study
Exclusion Criteria:
- known allergy or contraindication to morphine, paracetamol, or any opioid analgesic
- hemodynamic instability; fever (temperature > 38°C [100. 4°F])
- evidence of peritoneal inflammation
- documented or suspected pregnancy
- known or suspected aortic dissection or aneurysm
- use of any analgesic within 6 hours of ED presentation
- previous study enrollment Patients with known renal, pulmonary, cardiac, or hepatic
failure, as well as those with renal transplantation, were also excluded.
Locations and Contacts
Pamukkale University, Denizli, Turkey
Pamukkale University Hospital Emergency Department, Denizli 20020, Turkey
Additional Information
Starting date: January 2011
Last updated: March 31, 2011
|